ARWR Arrowhead Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ARWR

Price (delayed)

$21.87

Market cap

$2.71B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.76

Enterprise value

$2.77B

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger ...

Highlights
The net income has dropped by 92% year-on-year and by 45% since the previous quarter
ARWR's EPS has plunged by 89% YoY and by 44% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://arrowheadpharma.com
Peers: ALNY INO JNJ LGND

Key stats

What are the main financial stats of ARWR
Market
Shares outstanding
123.9M
Market cap
$2.71B
Enterprise value
$2.77B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
14.65
Price to sales (P/S)
12.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.24
Earnings
Revenue
$181.74M
EBIT
-$276.52M
EBITDA
-$262.45M
Free cash flow
-$402.7M
Per share
EPS
-$2.76
Free cash flow per share
-$3.75
Book value per share
$1.49
Revenue per share
$1.69
TBVPS
$5.74
Balance sheet
Total assets
$626.29M
Total liabilities
$452.57M
Debt
$118.58M
Equity
$160.41M
Working capital
$174.18M
Liquidity
Debt to equity
0.74
Current ratio
3.73
Quick ratio
3.46
Net debt/EBITDA
-0.23
Margins
EBITDA margin
-144.4%
Gross margin
100%
Net margin
-163.3%
Operating margin
-164.7%
Efficiency
Return on assets
-38.6%
Return on equity
-95.5%
Return on invested capital
-41%
Return on capital employed
-49.2%
Return on sales
-152.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ARWR stock price

How has the Arrowhead Pharmaceuticals stock price performed over time
Intraday
-6.1%
1 week
-3.27%
1 month
-21.58%
1 year
-34.87%
YTD
-28.53%
QTD
-23.53%

Financial performance

How have Arrowhead Pharmaceuticals's revenue and profit performed over time
Revenue
$181.74M
Gross profit
$181.74M
Operating income
-$299.41M
Net income
-$296.81M
Gross margin
100%
Net margin
-163.3%
Arrowhead Pharmaceuticals's net margin has shrunk by 194% YoY and by 91% QoQ
The operating margin has dropped by 192% year-on-year and by 93% since the previous quarter
The net income has dropped by 92% year-on-year and by 45% since the previous quarter
The operating income has dropped by 90% year-on-year and by 46% since the previous quarter

Growth

What is Arrowhead Pharmaceuticals's growth rate over time

Valuation

What is Arrowhead Pharmaceuticals stock price valuation
ARWR P/E details
P/E
N/A
P/B
14.65
P/S
12.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.24
ARWR's EPS has plunged by 89% YoY and by 44% from the previous quarter
The equity has plunged by 57% YoY and by 41% from the previous quarter
The price to book (P/B) is 23% higher than the last 4 quarters average of 11.9 and 20% higher than the 5-year quarterly average of 12.2
The price to sales (P/S) is 62% less than the 5-year quarterly average of 34.0 and 6% less than the last 4 quarters average of 13.7
The company's revenue fell by 35% YoY and by 25% QoQ

Efficiency

How efficient is Arrowhead Pharmaceuticals business performance
ARWR's ROS has plunged by 186% YoY and by 99% from the previous quarter
The company's return on equity has shrunk by 160% YoY and by 70% QoQ
The company's return on assets has shrunk by 90% YoY and by 57% QoQ
Arrowhead Pharmaceuticals's return on invested capital has shrunk by 52% YoY and by 52% QoQ

Dividends

What is ARWR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ARWR.

Financial health

How did Arrowhead Pharmaceuticals financials performed over time
ARWR's total assets is 38% higher than its total liabilities
ARWR's total assets is down by 30% YoY and by 18% QoQ
The quick ratio has decreased by 22% YoY and by 10% from the previous quarter
Arrowhead Pharmaceuticals's debt is 26% lower than its equity
The debt to equity has soared by 76% from the previous quarter
The equity has plunged by 57% YoY and by 41% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.